巧施分子“木马计” 撕掉肿瘤“隐身衣”

Core Insights - A significant breakthrough in cancer vaccine technology has been achieved by a research team led by Professor Chen Peng from Peking University, utilizing protein-targeted degradation techniques to transform cancer cells into active immune signals [1][2] - The new approach aims to address the issue of immune tolerance in cancer treatment, where a portion of patients do not respond to traditional immunotherapy due to cancer cells' ability to disguise themselves [1][2] Group 1 - The research team has developed a novel molecule called "intra-tumoral vaccine chimeras (iVAC)," which acts as a cancer cell identifier, disrupts immune "brakes," and delivers high-quality information to the immune system [2] - This new molecule can precisely infiltrate cancer cells, reprogramming them to become active immune messengers, thereby enhancing immune response [2] - The efficacy of the iVAC molecule has been validated through various experimental models, including cellular and mouse studies [2] Group 2 - The research team is actively working on the clinical translation of their findings, with plans to develop personalized cancer vaccines tailored to different patients in the future [2]